ADMA — ADMA BIOLOGICS, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 1368514 ·
Last close
$13.63
Market Cap
$3.02B
52W High
$20.46
52W Low
$7.21
ADV30
3,751,158
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 141,102,000 99,917,000 67,757,000 49,884,000 732,485,000 124,555,000 293,978,000
Jun 2026 124,395,000 86,277,000 52,445,000 37,822,000 684,210,000 136,020,000 276,002,000
Mar 2026 114,493,000 80,750,000 50,294,000 45,328,000 665,184,000 138,153,000 274,859,000
Dec 2025 139,163,000 88,816,000 62,751,000 49,379,000 624,242,000 87,630,000 146,922,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$140,795,000
Investing CF
$-2,196,000
Financing CF
$-75,429,000
CapEx
$-8,196,000
Dividends Paid
—
Buybacks
$-189,202,000
EPS Diluted TTM
$0.77
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-28,619,000
Inventory
$266,115,000
Receivables
$169,223,000
ST Investments
—
EBIT TTM
$245,145,000
Pretax Income TTM
$234,563,000
Interest Exp TTM
$10,582,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$519,152,992
EBITDA
$240,702,000
Free Cash Flow
$90,261,624
Enterprise Value
$2,902,455,296
Total Cash
$124,555,000
Total Debt
$202,804,000
Shares Out
221,854,389
Trailing EPS
$0.77
Book Value
$1.97
ROE
41.9%
ROA
22.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 510,173,000 191,443,000 146,930,000 624,242,000 146,922,000 477,320,000 50,396,000
Dec 2024 426,454,000 138,983,000 197,673,000 488,678,000 139,660,000 349,018,000 118,672,000
Dec 2023 258,215,000 21,632,000 -28,239,000 329,182,000 193,976,000 135,206,000 8,800,000
Dec 2022 154,080,000 -39,365,000 -65,904,000 348,461,000 196,487,000 151,974,000 -59,508,000

TTM Snapshot

Revenues TTM
$512,275,000
NetIncome TTM
$168,957,000
OpCashFlow TTM
—
Assets (Latest)
$684,210,000
Forward EPS
$1.01

Max Pain — expiry 2027-01-15

max pain strike: $13.00 · spot: $13.56 · call oi: 13,262 · put oi: 2,024

Peers — same industry

TickerNameMarket CapLastDaily %
VCEL Vericel Corp $2.95B $57.88 —
DNLI Denali Therapeutics Inc. $2.89B $18.00 —
IOVA IOVANCE BIOTHERAPEUTICS, INC. $3.48B $7.53 —
RLAY Relay Therapeutics, Inc. $3.64B $16.47 —
TARS Tarsus Pharmaceuticals, Inc. $3.86B $78.20 —

News headlines (Yahoo Finance, 1h cache)

ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?
2026-11-11 16:41 · Yahoo
Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average
2026-11-06 13:35 · Yahoo
Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average
2026-11-06 13:30 · Yahoo
Q3 Earnings Beat Might Change The Case For ADMA Biologics Stock
2026-11-06 10:12 · Yahoo
ADMA Biologics (ADMA) Q3 2026 Earnings Call Transcript
2026-11-05 18:13 · Yahoo
ADMA Biologics Inc (ADMA) Q3 2026 Earnings Call Highlights: Asceniv Surge Drives Margin ...
2026-11-05 17:08 · Yahoo
Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates
2026-11-04 23:45 · Yahoo
ADMA Biologics Q3 Earnings Call Highlights
2026-11-04 23:14 · Yahoo
Adma Biologics: Q3 Earnings Snapshot
2026-11-04 22:41 · Yahoo
ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-04 21:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.